Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup

Annals of Hematology

Volumn 84, Issue 9, 2005, Pages 569-571

  Giagounidis, A A N ^a   Germing, U ^b   Strupp, C ^b   Hildebrandt, B ^b   Heinsch, M ^a   Aul, C ^a  

^a ST JOHANNES HOSPITAL   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Cytogenetics; Del(5q); Lenalidomide; Myelodysplastic syndromes; Therapy

Indexed keywords

LENALIDOMIDE;

5Q- SYNDROME; AGED; ARTICLE; BLOOD CELL COUNT; CASE REPORT; CHROMOSOME ANALYSIS; CYTOGENETICS; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG RESPONSE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KARYOTYPE; MAJOR CLINICAL STUDY; NAUSEA AND VOMITING; PRIORITY JOURNAL; PROGNOSIS; PRURITUS; REMISSION; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; CHROMOSOME ABERRATIONS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 5; HUMANS; KARYOTYPING; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; REMISSION INDUCTION; SURVIVAL RATE; THALIDOMIDE;

EID: 23944489636     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-005-1054-0     Document Type: Article

References (9)

1. Giagounidis AA, Germing U, Wainscoat JS, Boultwood J, Aul C (2004) The 5q-syndrome. Hematology 9:271-277 10.1080/10245330410001723824
2. Giagounidis AA, Germing U, Haase S, Hildebrandt B, Schlegelberger B, Schoch C, Wilkens L, Heinsch M, Willems H, Aivado M, Aul C (2004) Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31. Leukemia 18:113-119 10.1038/sj.leu.2403189
3. Giagounidis AA, Haase S, Germing U, Schlegelberger B, Wilkens L, Busche G, Kreipe HH, Wysk J, Grips KH, Grabenhorst U, Rothmann F, Lubbert M, Ganser A, Aivado M, Heinsch M, Aul C (2005) Treatment of myelodysplastic syndrome with isolated del(5q) including bands q31-q33 with a combination of all-trans-retinoic acid and tocopherol-alpha: A phase II study. Ann Hematol 84(6):389-394 10.1007/s00277-005-1027-3
4. List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D, Rimsza L, Heaton R, Knight R, Zeldis JB (2005) Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 352:549-557 10.1056/NEJMoa041668
5. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C (1982) Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189-199 1:STN:280:Bi2B3cnlt1M%3D
6. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079-2088 1:CAS:528:DyaK2sXhvVars70%3D
7. Bartlett JB, Dredge K, Dalgleish AG (2004) The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 4:314-322 10.1038/nrc1323
8. Toyama K, Ohyashiki K, Yoshida Y, Abe T, Asano S, Hirai H, Hirashima K, Hotta T, Kuramoto A, Kuriya S et al (1993) Clinical implications of chromosomal abnormalities in 401 patients with myelodysplastic syndromes: A multicentric study in Japan. Leukemia 7:499-508 1:STN:280:ByyB3Mfis1A%3D
9. Strupp C, Hildebrandt B, Germing U, Haas R, Gattermann N (2003) Cytogenetic response to thalidomide treatment in three patients with myelodysplastic syndrome. Leukemia 17:1200-1202 10.1038/sj.leu.2402894